Cowen Cuts Price Target on Celldex (CLDX) Following 2Q and Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cantor Fitzgerald Cuts Price Target on Celldex (CLDX) to $31 Following Rintega Filing Delay
August 11, 2015 10:10 AM EDTCantor Fitzgerald maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $38.00), following its decision to delay BLA filing for Rintega. Analyst Mara Goldstein said that filing for Rintega is not likely until the completion of ACT IV. ACT IV is expected... More
Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on Weakness
August 11, 2015 8:11 AM EDTRoth Capital trims its price target on Celldex Therapeutics (Nasdaq: CLDX) from $43 down to $39 following Q2 results issued after markets closed Monday.
Analyst Joseph Pantginis commented, The key point to the 2Q15 results call, which we believe will drive perception for the... More
Brean Capital Cuts Price Target on Celldex (CLDX) Following Talks with FDA
August 11, 2015 7:07 AM EDTBrean Capital maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $35.00), following company talks with the FDA. CLDX has received enough feedback to conclude that it will not file Rintega for Accelerated Approval in recurrent GBM.
Analyst... More
Celldex (CLDX) Reports Q2 Loss of $0.33
August 10, 2015 4:51 PM EDTCelldex (NASDAQ: CLDX) reported Q2 EPS of ($0.33), versus ($0.32) reported last year. Revenue for the quarter came in at $2.2 million, versus $592 thousand reported last year.
For earnings history and earnings-related data on Celldex (CLDX) click here.
... More